Allogeneic haematopoietic SCT is a standard therapy for many patients with haematological diseases. A major aim of public umbilical cord blood (UCB) banking is to establish an inventory with a large HLA diversity. Few studies have compared HLA diversity between UCB banks and volunteer unrelated donor (VUD) registries and examined whether UCB banks indeed collect more units with rare alleles and haplotypes. This study compares HLA-A/B/DRB1 allele frequencies and inferred A/B/DRB1-haplotypes in 1602 UCB units and 3093 VUD from two centres in distinct recruitment areas in Switzerland. The results show that the frequencies of HLA-DRB1 alleles as well as of the HLA-A/B/DRB1 haplotypes differ between UCB and VUD. Ten DRB1 alleles occurred at a 2-to 12-fold higher relative frequency in UCB than in VUD and 27 rare alleles were identified in UCB. Out of these 27 alleles, 15 were absent in the entire VUD data set of the national registry. This difference in allele frequencies was found only by intermediate/highresolution typing. Targeted recruitment of UCB units from non-Caucasian donors could further increase HLA allele and haplotype diversity of available donors. Intermediate or high-resolution DNA typing is essential to identify rare alleles or allele groups.
Introduction
Allogeneic haematopoietic SCT is a standard treatment for defined haematological and genetic disorders, such as leukaemia, lymphoma, aplastic anaemia haemoglobinopathies, immunodeficiency syndromes or inborn errors of metabolism. The success of haematopoietic SCT is largely determined by the degree of HLA-match between donor and recipient. 1, 2 Since the early days of haematopoietic SCT, an HLA genotypically identical sibling has been the donor of choice. About 30% of patients have an HLA identical sibling, 30-50% find a fully matched voluntary unrelated donor (VUD), whereas for 20-40%, the search remains unsuccessful. Through the BMDW (Bone Marrow Donors Worldwide) registry, a high percentage of Caucasian patients but far fewer patients of racial minorities find suitably HLA-matched donors. 3 For those patients alternative stem cell sources are warranted.
Over 6000 umbilical cord blood (UCB) transplants have been performed worldwide from related and unrelated UCB donors for adult and paediatric patients. [4] [5] [6] In UCB transplants, long-term survival is strongly associated with cell dose and degree of HLA matching. [5] [6] [7] The data available so far suggest that a higher degree of HLA mismatching is permitted in UCB transplants, probably due to the immaturity of the T-cell compartment of the newborn but, given equal cell dose, a better matched donor is usually preferred. Whereas VUD selection is usually based on HLA-A/B/C/DRB1/DQB1 (10/10) allele level matching, most UCB transplants are still selected on the basis of HLA-A and -B low-resolution and DRB1 intermediate/high-resolution matching only. 8 Furthermore, compared with BM, UCB is easy to procure, has no risk to the donor and the risk of transmitting infections is low. This has encouraged the foundation of numerous public UCB banks and led to an increasing number of UCB transplants. 9 It is a declared major aim of public UCB banking (www.worldmarrow.org) to provide transplants for ethnic minorities and to support a large inventory of rare HLA-alleles and haplotypes in addition to the marrow donor registries. Population-based HLA allele and haplotype frequency analyses are useful tools to assess the diversity of a donor population and to optimize search strategies. [10] [11] [12] [13] [14] The national organization Swiss Blood stem cells (SBsc) registers UCB from two Swiss cord blood banks in two hospitals with distinct recruitment areas and different sociocultural background and also VUD recruited by the country-wide blood banks. Presently there is little information 15, 16 about whether cord blood banks recruit donors with HLA-alleles and haplotypes different from adult donor registries within the same geographical area.
Materials and methods

Study design
This retrospective analysis compares the distribution of HLA-A, -B and -DRB1 alleles and inferred HLAhaplotype frequencies in UCB donors and VUD from two centres in Switzerland with distinct local background and different migrant populations; Basel, in the Germanspeaking part of Switzerland, and Geneva, in the Frenchspeaking part of Switzerland (see Table 1 ). UCB was collected in the obstetrical units of the two University Hospitals, whereas VUD were recruited by the blood banks affiliated with the hospital at the same two centres. All UCB units and VUD were registered with the Swiss Blood stem cells registry.
UCB and unrelated donors
All UCB units and unrelated donors from centres 1 and 2 registered as per end of September 2006 were included in this study. A total of 1602 UCB units were included, 1094 from centre 1 and 508 from centre 2. These were compared with a total of 3093 unrelated donors recruited by the blood banks, 1838 from centre 1 and 1255 from centre 2. Recruitment of UCB started in 1998 and recruitment of VUD started in 1988. UCB was collected in centres 1 and 2 following ethical committee approval and informed consent of the mother.
HLA typing HLA-A, -B and -DRB1 typing of all UCB was performed at the Swiss national reference laboratory for Histocompatibility (LNRH, Laboratoire National de Re´fe´rence pour l'Histocompatibilite´, Geneva, Switzerland) by molecular typing using PCR-sequence-specific primers (SSP; Genovision, Milan Analytica, Magden, Switzerland) and, since 2002, by PCR-sequence-specific oligonucleotide probe (SSO) reverse hybridization on microbeads (Luminex Technology, InGen, Chilly Mazarin, Switzerland, Lab Type, One Lambda). HLA-A and -B typing of the VUD was performed by serology (AB120 tray, Biotest AG, Othmarsingen, Switzerland) in the two recruitment centres, and HLA-DRB1 of all donors was performed by reverse PCR-SSO hybridization, first on microtiter plates (bioMe´rieux, Geneva, Switzerland), and, since 2002, by the Luminex technique. All rare alleles identified by PCR-SSO either as single allele or with ambiguities have been verified by PCR-SSP or sequencebased typing.
Low-resolution HLA typing data (serology or two-digit molecular typing) was available for all cord blood units and all unrelated donors. Intermediate/high-resolution typing data (four-digit typing with all ambiguities reported, as determined by the PCR-SSO microbead assay) was available for 99.9% of the UCB units and for 97.8% of the unrelated donors for HLA-DRB1.
Comparison of antigen/allele distribution among UCB and VUD Comparisons of allele frequencies were performed for HLA-A, -B and DR at two-digit typing for all UCB and VUD. Owing to the low number of VUD with intermediate-resolution typing for HLA-A and -B, comparisons at the four-digit level could reasonably be performed only for DRB1. For comparisons, ratio of antigen/allele frequencies between UCB or VUD, or between centres were calculated.
Rare alleles
Alleles occurring with a frequency of o0.05% in the Caucasian population were considered as rare. Rare alleles in the Caucasian population might eventually become frequent in a population with a different ethnic background, for example, DRB1*0302 or *1304. Rare alleles were compared between the UCB and VUD population and with documented allele frequency databases (www. allelefrequencies.net). When available, the population and/ or ethnic background in which each of the rare alleles was found most frequently was indicated.
Haplotype analysis
Haplotype frequencies of UCB and unrelated donors were estimated from phenotype data using the expectationmaximization algorithm in an improved version of the implementation described by C Mu¨ller et al. 10 These estimated haplotype frequencies were compared with those computed from 400 000 donors of the National Marrow Donor Program registry (www.marrow.org).
Statistical analysis
Comparisons of allele frequencies between banks and centres, and comparisons of haplotype frequencies among UCB and VUD were performed using the w 2 test for proportions. Owing to multiple comparisons only P-values o0.001 are considered as significantly different. 
Results
Comparison of HLA data from UCB and unrelated donors
The comparison of HLA-A, -B and -DRB1 two-digit allele group frequencies showed no difference between UCB donors and VUD (data shown only for HLA DRB1 in Figure 1a ). In contrast, comparison of DRB1* four-digit allele frequencies between UCB and VUD showed major frequency differences ( Figure 1b ). There were also differences between the two centres: the DRB*1503 allele was found among the UCB of centre 1 only, whereas the DRB*0805, *0806 and *1318 alleles were found among the UCB of centre 2 only. DRB1*1111 was found among the VUD of centre 1 only, whereas DRB1*1115, *1305 and *1324 were found among the VUD of centre 2 only. DRB*1304 was represented in centre 2 only and not in centre 1, but occurred among UCB as well as VUD of centre 2. Differences in DRB1 allele frequencies were less pronounced when comparing UCB or VUD of both banks (Figures 1c and d) . The allele DRB1*1305, however, occurred nearly eight times more frequently in VUD of centre 1 than in VUD of C2 ( Figure 1d ). Table 3 shows a list of rare HLA-A, -B and -DRB1 alleles (frequency of o0.05%) in Caucasian populations identified in UCB. The alleles were first identified by reverse PCR-SSO intermediate/high-resolution typing, and confirmed by resolution of the ambiguities through PCR-SSP typing or sequence-based typing. Twenty-seven different alleles considered as rare in Caucasians were found in the UCB data set. As the number of HLA-A and -B DNA-typed VUD from centres 1 and 2 was too low to allow for a direct comparison, we searched for the presence of these alleles in the entire data set of VUD and found that 56% (15 alleles) were totally absent in the national database. Moreover, these alleles had not been observed previously in the patient/donor samples analysed by the LNRH during the past 10 years in the process of unrelated haematopoietic stem cell donor searches. Three out of the 4 rare DRB1 alleles identified in UCB were not found in the donors of centres 1 and 2.
Rare alleles
Seven out of the 27 rare alleles in the UCB occurred more than once, leading to a total of 44 rare alleles in cord blood units. Of the 27 rare alleles observed in UCB samples, 7 have been described most frequently in African populations, 7 in Asian populations, 5 in South American populations, 2 in Europeans, 1 in Australians and 1 in Melanesians. Four rare alleles, DRB1*1111, *1115, *1324 and *1417, were detected in VUD only ( Table 2 ). Each of them was detected in one donor only and they have all been documented previously in Caucasians. Table 4 lists the 20 most common haplotypes found in UCB donors (centres 1 and 2) and their respective frequencies. For comparison, the haplotype frequencies in VUD from centres 1 and 2 and those reported by the National Marrow Donor Program for Caucasian populations are also shown. There was a significant difference between UCB and VUD in the frequency of three haplotypes (2-18-1104, 2-44-1104 and 24-18-1104). Furthermore, there was a marked difference in the frequency of the following haplotypes: 3-7-1501, 3-35-0101 and 2-35-0101. The haplotypes 2-18-1104, 2-44-1104, 2-35-0101 and 24-18-1104 also occurred more frequently in UCB than in VUD. Interestingly, these four haplotypes were not found among the 30 most frequent haplotypes computed for the Caucasian donors of the National Marrow Donor Program registry. The two haplotypes 3-7-15 and 3-35-1 occurred at a significantly reduced (30-40%) frequency in the UCB bank but were among the 10 most frequent haplotypes in VUD and donors of the National Marrow Donor Program registry.
HLA-haplotypes
Discussion
The aim of the study was to compare the HLA-A/B/DRB1 allele and haplotype frequencies in UCB units and VUD recruited in the same region. Results show that UCB banks in Switzerland recruit units with HLA allele frequencies that differ considerably from those found in VUD recruited through the blood banks. More importantly, differences are disclosed at an intermediate/high-resolution typing level only. HLA-A/B/DRB1 haplotype frequencies were also different between UCB and VUD, even for some of the most frequent haplotypes in Caucasian populations. Despite the lower number of UCB samples compared with VUD, a large number of rare alleles were identified in the UCB units. This most likely results from recruitment of non-Caucasian individuals in UCB banks.
Even though neither of the centres specifically targets minorities for UCB donation and UCB donors have to respond to the same eligibility criteria of the Swiss Red Cross for VUD, UCB donors appear to be immunogenetically markedly different from VUD. We found 27 rare alleles, as defined with a frequency o0.05% in Caucasian populations, with 56% of those being absent from the registry and also from the reference laboratory database. As most of these alleles have been reported to occur mainly in non-Caucasian populations (e.g., A*0202, B*1535 or DRB1*1304), more UCB donors may belong to ethnic minorities. The large number of rare alleles found in the UCB group suggests that the UCB banks recruit more often in the non-Caucasian populations compared with the transfusion centres recruiting VUD. One of the centres presents informed consent forms for UCB recruitment in five different languages, a fact that might support the recruitment of minorities. Alleles found in UCB only, 2 alleles found in VUD only, 3 alleles found in C1 only, 4 alleles found in C2 only. Combination of two marks, that is, 1, 3 means that the allele is found in only one of the stem cell sources (that is, in UCB only) and in only one centre (that is, centre 1).
Allocation of an allele to a 'rare allele' category is obviously dependent on frequency cut-off and on the reference population. Recently, Cano et al. 17 created a catalogue of common and well-documented alleles, which was defined as alleles occurring with frequencies greater than 0.001 in any reference population or alleles that have been observed in at least three unrelated individuals. In view of the very large population samples investigated by these authors, it is not unexpected that most of the rare alleles described in this study are reported in this catalogue of common and well-documented alleles. It is noteworthy that two alleles (A*6826 and B*4417) detected in the UCB samples have not been reported as common and welldocumented alleles.
Switzerland has one of the highest immigrant populations of any European country with more than one million residents, as 23% of its 7.5 million residents are foreign. There is a clear-cut difference in donor availability among the Caucasian population and the migrants. Rare alleles and rare haplotypes are therefore of great importance, as they may be rare among Caucasians but frequent among other ethnicities.
Migrants are more strongly represented among mothers giving birth in public hospitals than among volunteer blood donors registering for marrow donation. Brown et al. 15 showed that UCB units of the London Cord Blood Bank are more likely to be derived from ethnic minorities, although they represented only 2% of the VUD in the British Bone Marrow registry. Furthermore, their UCB units show an HLA profile that differs from that of their VUD. These results are confirmed by our study. Obstetric wards in public hospitals may be well placed to recruit ethnic minorities, as these populations concentrate in larger cities and in the publicly available medical facilities. By contrast, VUD registries usually reach blood donors who are more likely to be indigenous.
Regarding immunogenetic diversity, the relative distribution of allelic subtypes in UCB vs VUD, as documented for the DR4, DR11, DR13 or DR14 serotypes (Table 2 , Figures 1a-f) , is perhaps more relevant than the high number of rare class I and II alleles because it comprises a significantly larger number of individual phenotypes. Indeed, this should contribute to increase the haplotypic diversity at the four-digit level. This may occur either because a given allele, which is more frequent in the UCB than in the VUD, could increase the diversity within two-digit-identical ABDR haplotypes or because such an allele may be associated with a different allele by linkage disequilibrium. A striking example is the A2-B18-DRB1*1104 haplotype that occurred three times more frequently in the UCB than in the VUD (Table 4) . Interestingly, 4 out of 5 DR11-positive haplotypes among the 20 most frequent haplotypes in UCB exhibited the DRB1*1104 allele, which seems to be less frequent in the DR11-positive VUD. With four haplotypes being more frequent in UCB, and two haplotypes more frequent in the VUD study group (Table 4) , our analysis reveals important differences among the 20 most frequent haplotypes between UCB banks and VUD registries.
HLA high-resolution matching has become standard practice in unrelated haematopoietic SCT. It is most likely to be beneficial in cord blood transplantation as well. For historical reasons, UCB is mostly typed at two-digit level for HLA-A and -B and at four-digit level for HLA-DRB1. Whereas VUD selection is based on HLA-A, -B, -C, -DRB1 and -DQB1 (10/10) allele level high-resolution matching, most UCB transplants are commonly selected on the basis of HLA-A, and -B low-resolution and -DRB1 on intermediate/high-resolution matching level only. At present, only a limited number of cord blood units are typed at intermediate-or high-resolution level. Concerns about cost efficiency hold most of the HLA laboratories and donor registries back from switching to four-digit typing. Our The comparison of allele frequencies is shown in Figure 1b .
study shows that intermediate/high-resolution typing of UCB reveals different HLA-alleles and haplotypes than in VUD. This difference is more important at the four-digit typing level as shown in Figures 1a and b and by the higher number of rare alleles typed in UCB. This typing level is also relevant for the discrimination of major allele groups within the DR4, DR11, DR13 or DR14 serotypes. Discrimination of allele groups within B-serotypes, such as B*4402 vs B*4403 or B*4405, will also impact on HLA-C compatibility status by linkage disequilibrium and typing of HLA-C and HLA-DQB1 in UCB should be considered.
Owing to the relatively small number of UCB units and VUD, these results should be interpreted with caution. As we find rare events that are difficult to compare statistically, we avoided P-values to a great extent, and our data are mainly descriptive. Furthermore, given the heterogeneity in the ethnic background, probably more so in the UCB than in the VUD, all information on haplotype distribution has to be interpreted cautiously. The strength of our study is that both cohorts, UCB and VUD, were from the same geographic region and were typed by the same techniques at the same laboratory. However, the two cohorts are recruited differently, donors through the blood banks and UCB through the maternity wards. We assume that this difference is much more important than any possible shift in population over the recruitment period.
We propose to perform HLA-A, -B, -C and -DRB1 intermediate/high-resolution typing for UCB banks to improve the detection rate of rare alleles and haplotypes. This typing level is relevant also for the discrimination of major allele groups within the DR4, DR11, DR13 or DR14 serotypes, and discrimination of allele groups within B-serotypes will also impact on HLA-C compatibility status of selected UCB units by linkage disequilibrium. We also propose to target ethnic minorities for UCB donation specifically. Indeed, it might be easier to motivate Column 2 shows the number of times the allele has been detected in our UCB data set. The third column shows the number of populations in which the allele has been detected and the number of populations screened for this allele. Column 4 shows the population in which the allele is most frequently found. Column 5 shows the range of allele frequency. Source: www.allelefrequencies.net. Four rare alleles, DRB1*1111, *1115, *1324 and *1417, were detected in VUD only. a Alleles not detected at the LNRH within the last 10 years in VUD searches. NA ¼ not applicable.
persons from different cultural backgrounds to donate cord blood in obstetrical wards than to register for BM/PBSC donation. With 11 million donors registered and over 300 000 cord blood units already stored worldwide, the future challenge will be to broaden immunogenetic diversity by improving the typing level and by targeting UCB donors from minorities. 
